Sorrento Therapeutics (SRNE) 10-Q2023 Q2 Quarterly report

Filed: 11 Aug 23, 8:00pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	Coll freshman Avg

New words: abeyance, adequacy, affiliated, altered, attrition, auction, bad, bar, bid, bidder, Binomial, block, blocked, blue, Bond, broker, called, Cap, capacity, Certificate, Coupon, daily, de, defense, derecognition, detail, dispose, distraction, drawn, eCapital, Eligible, erosion, estate, expedited, explained, flat, flexibility, freely, fundamentally, grace, guaranty, hand, Healthcare, heard, hereof, Holdback, horse, image, incentivize, indemnify, indirectly, instruction, intensive, intercreditor, Journal, junior, kind, Lattice, line, mediation, merged, monthly, morale, mutually, Oramed, postpetition, prime, priming, proceed, prohibited, promote, qualification, quickly, refusal, requisite, resell, reverted, revolving, ROU, running, seller, serve, Shanghai, sit, sky, solicit, SPAC, sponsor, stalking, Street, sum, sweep, technique, thousand, viable, voluntarily, Wall, warrant

Removed: enforce, receipt

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

SRNE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATIONS OF

PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Henry Ji, principal executive officer of Sorrento Therapeutics, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to my knowledge:

The Quarterly Report on Form 10-Q of the Company for the period ended June 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date:	August 11, 2023	By:	/s/ Henry Ji, Ph.D.
			Henry Ji, Ph.D.
			Chairman of the Board of Directors, Chief Executive Officer and President
			(Principal Executive Officer)

I, Elizabeth Czerepak, principal financial officer of Sorrento Therapeutics, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to my knowledge:

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date:	August 11, 2023	By:	/s/ Elizabeth Czerepak
			Elizabeth Czerepak
			Executive Vice President and Chief Financial Officer
			(Principal Financial Officer)

A signed original of these certifications has been provided to Sorrento Therapeutics, Inc. and will be retained by Sorrento Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of Sorrento Therapeutics, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.